Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations

被引:23
|
作者
Le, V. N. P. [1 ,2 ]
Robins, E. [3 ]
Flament, M. P. [1 ,2 ]
机构
[1] Univ Lille Nord France, Coll Pharm, Lille, France
[2] INSERM U 1008, Lille, France
[3] APTAR Pharma, F-27100 Le Vaudreuil, France
关键词
Gas permeation; DPI performance; Fluticasone; Agglomerates; Powder aerosolisation; IN-VITRO DEPOSITION; SALMETEROL XINAFOATE; LACTOSE CARRIER; PARTICLE-SIZE; RESPIRABLE PARTICLES; AEROSOL DISPERSION; SURFACE-PROPERTIES; DRUG; INHALATION; MIXTURES;
D O I
10.1016/j.ejpb.2011.12.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Due to their small size, the respirable drug particles tend to form agglomerates which prevent flowing and aerosolisation. A carrier is used to be mixed with drug in one hand to facilitate the powder flow during manufacturing, in other hand to help the fluidisation upon patient inhalation. Depending on drug concentration, drug agglomerates can be formed in the mixture. The aim of this work was to study the agglomeration behaviour of fluticasone propionate (FP) within interactive mixtures for inhalation. The agglomerate phenomenon of fluticasone propionate after mixing with different fractions of lactose without fine particles of lactose (smaller than 32 pm) was demonstrated by the optical microscopy observation. A technique measuring the FP size in the mixture was developed, based on laser diffraction method. The FP agglomerate sizes were found to be in a linear correlation with the pore size of the carrier powder bed (R-2 = 0.9382). The latter depends on the particle size distribution of carrier. This founding can explain the role of carrier size in de-agglomeration of drug particles in the mixture. Furthermore, it gives more structural information of interactive mixture for inhalation that can be used in the investigation of aerosolisation mechanism of powder. According to the manufacturing history, different batches of FP show different agglomeration intensities which can be detected by Spraytec (R), a new laser diffraction method for measuring aerodynamic size. After mixing with a carrier, Lactohale LH200, the most cohesive batch of FP, generates a lower fine particle fraction. It can be explained by the fact that agglomerates of fluticasone propionate with very large size was detected in the mixtures. By using silica-gel beads as ball-milling agent during the mixing process, the FP agglomerate size decreases accordingly to the quantity of mixing aid. The homogeneity and the aerodynamic performance of the mixtures are improved. The mixing aid based on ball-milling effect could be used to ameliorate the quality of inhalation mixture of cohesive drug, such as fluticasone propionate. However, there is a threshold where an optimal amount of mixing aids should be used. Not only the drug des-aggregation reaches its peak but the increase in drug-carrier adhesion due to high energy input should balance the de-agglomeration capacity of mixing process. This approach provides a potential alternative in DPI formulation processing. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:596 / 603
页数:8
相关论文
共 50 条
  • [31] The Role of Fines in the Modification of the Fluidization and Dispersion Mechanism Within Dry Powder Inhaler Formulations
    Jagdeep Shur
    Haggis Harris
    Matthew D. Jones
    J. Sebastian Kaerger
    Robert Price
    Pharmaceutical Research, 2008, 25 : 1631 - 1640
  • [32] The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations
    Shur, Jagdeep
    Harris, Haggis
    Jones, Matthew D.
    Kaerger, J. Sebastian
    Price, Robert
    PHARMACEUTICAL RESEARCH, 2008, 25 (07) : 1931 - 1940
  • [33] Fluticasone propionate/salmeterol (Wixela® Inhub®) dry-powder inhaler in asthma and COPD: a profile of its use in the USA
    Blair, Hannah A.
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (12) : 583 - 591
  • [34] Fluticasone propionate/salmeterol (Wixela® Inhub®) dry-powder inhaler in asthma and COPD: a profile of its use in the USA
    Hannah A. Blair
    Drugs & Therapy Perspectives, 2019, 35 : 583 - 591
  • [35] Efficacy of fluticasone metered-dose inhaler and dry powder inhaler for pediatric asthma
    Miyahara, Hiroaki
    Korematsu, Seigo
    Nagakura, Tomokazu
    Izumi, Tatsuro
    PEDIATRICS INTERNATIONAL, 2008, 50 (01) : 103 - 108
  • [36] Particle surface coating for dry powder inhaler formulations
    Huang, Yijing
    Patil, Chanakya D.
    Arte, Kinnari Santosh
    Zhou, Qi
    Qu, Li
    EXPERT OPINION ON DRUG DELIVERY, 2025,
  • [37] Pharmacokinetics and Pharmacodynamics of Fluticasone Propionate and Salmeterol Delivered as a Combination Dry Powder from a Capsule-Based Inhaler and a Multidose Inhaler in Asthma and COPD Patients
    Daley-Yates, Peter T.
    Mehta, Rashmi
    Chan, Robert H.
    Despa, Simona X.
    Louey, Margaret D.
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2014, 27 (04) : 279 - 289
  • [38] Influence of crystal form of ipratropium bromide on micronisation and aerosolisation behaviour in dry powder inhaler formulations
    Shur, Jagdeep
    Kubavat, Harshal A.
    Ruecroft, Graham
    Hipkiss, David
    Price, Robert
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (09) : 1326 - 1336
  • [39] LONG-TERM SAFETY OF FLUTICASONE PROPIONATE AND FLUTICASONE PROPIONATE/SALMETEROL MULTIDOSE DRY POWDER INHALERS IN ASTHMATIC PATIENTS
    Mansfield, L.
    Yiu, G.
    Sakov, A.
    Liu, S.
    Caracta, C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S65 - S65
  • [40] The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma
    Nugent, Courtney
    Yiu, Gloria
    Song, Sharon
    Caracta, Cynthia
    JOURNAL OF ASTHMA, 2018, 55 (08) : 898 - 906